Johnson & Johnson's CARVYKTI Is The First And Only Cell Therapy To Significantly Extend Overall Survival Versus Standard Therapies For Patients With Multiple Myeloma As Early As Second Line; 45% Reduction In Risk Of Death Achieved With CARVYKTI After...
Johnson & Johnson's CARVYKTI Is The First And Only Cell Therapy To Significantly Extend Overall Survival Versus Standard Therapies For Patients With Multiple Myeloma As Early As Second Line; 45% Reduction In Risk Of Death Achieved With CARVYKTI After...
Johnson & Johnson's CARVYKTI Is The First And Only Cell Therapy To Significantly Extend Overall Survival Versus Standard Therapies For Patients With Multiple Myeloma As Early As Second Line; 45% Reduction In Risk Of Death Achieved With CARVYKTI After Three-year Follow-up In Landmark CARTITUDE-4 Study
CARVYKTI是强生公司首个且唯一的细胞疗法，与标准疗法相比显著延长多发性骨髓瘤患者整体生存期，早至于二线；在标志性CARTITUDE-4研究的三年后随访中，CARVYKTI的死亡风险降低45%。
45 percent reduction in risk of death achieved with CARVYKTI after three-year follow-up in landmark CARTITUDE-4 study
CARVYKTI在标志性CARTITUDE-4研究的三年后随访中，死亡风险降低45%。
Data featured in a late-breaking oral presentation at the 2024 International Myeloma Society Annual Meeting
数据在2024年国际骨髓瘤学会年会上作为晚报口头报告的特色展示。
RIO DE JANEIRO, Sept. 27, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today long-term results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI (ciltacabtagene autoleucel) significantly extended overall survival (OS) in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI), reducing the risk of death by 45 percent versus standard therapies of pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd).1 With these data, CARVYKTI is now the first and only cell therapy to improve OS versus standard therapies for patients with lenalidomide-refractory multiple myeloma as early as second line.1 Findings were featured as a late-breaking oral presentation at the 2024 International Myeloma Society (IMS) Annual Meeting (Abstract #OA-65).1
2024年9月27日，里约热内卢 / PRNewswire -- 强生公司（纽交所：JNJ）今日宣布来自第3期CARTITUDE-4研究的长期结果，显示单次注射CARVYKTI（西达卡巴标记细胞自体淋巴细胞）在曾接受至少一种前线疗法的多发性骨髓瘤患者中显著延长整体生存期（OS），包括蛋白酶体抑制剂（PI），将死亡风险降低45%与标准疗法泊马利度胺、硼替佐米和地塞米松（PVd）或达美康胺、泊马利度胺和地塞米松（DPd）相比。有了这些数据，CARVYKTI现在是第一个也是唯一一个细胞疗法，可以早至于二线改善OS，与标准疗法相比对多发性骨髓瘤患者的莱那利胺耐药变体。发现在2024年国际骨髓瘤学会（IMS）年会上作为晚报口头报告（摘要编号 #OA-65）。